Ken H.
- Country
- Germany
- Department
- Nuclear Medicine
Research Overview
- Evaluation of Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Advanced Unresectable or Metastatic NSCLC, BC, PDAC, and CRC.
- Phase Ib Dose-Escalation Study of [177Lu]Lu-NeoB with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and as Monotherapy in Recurrent Glioblastoma
- Phase I Study of [177Lu]Lu-DFC413 and [68Ga]Ga-NNS309 in Patients with Advanced or Metastatic Solid Tumors
Data & Insights
Has run more than one trial at 97 of 166 partner sites.
Specializations
Oncological Focus
Specializes in advanced prostate cancer treatment, particularly focusing on metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive metastatic conditions.
- Prostate Cancer Therapies
- Oligometastatic Disease Management
- Hormone-Sensitive Cancer Treatment
Specialized Cancer Areas
Expertise in treating various advanced cancers including breast carcinoma, glioblastoma, and neuroendocrine tumors. Particular focus on gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- Breast Cancer Innovations
- Brain Tumor Treatment
- Neuroendocrine Therapies
Therapeutic Approaches
Employs advanced radioimmunotherapy techniques and targeted molecular treatments. Specializes in lutetium-based therapies and peptide receptor radionuclide therapy (PRRT).
- Radiopharmaceutical Applications
- Molecular Targeting
- Combination Therapy Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.